New Data Presented at ASTRO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men
Findings are from the prospective, multicenter VANDAAM trial
Excerpt from the Press Release:
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced that new data from the multicenter, prospective VANDAAM trial show that the Decipher Prostate Genomic Classifier accurately predicts aggressive prostate cancer among African American men with early-stage disease. The findings confirm that the market-leading genomic test offers clinicians an improvement over clinical factors alone in guiding prostate cancer treatment decisions for African American men, a population that is disproportionately impacted by the disease. The new data were shared today in an oral presentation at ASTRO 2024, the annual meeting of the American Society for Radiation Oncology, in Washington, D.C.
African American men are more than 70% as likely to be diagnosed with prostate cancer and more than twice as likely to die of the disease, compared to white men, according to the American Cancer Society.1 Despite this, few prospective studies have specifically sought to examine the disease at a genomic level in this population.
“We intentionally recruited African American men into the VANDAAM trial to enable a one-to-one match with non-African American men with similar clinical factors,” said Kosj Yamoah, M.D., Ph.D., chair of the Department of Radiation Oncology at the H. Lee Moffitt Cancer Center & Research Institute and presenter of the data at the ASTRO meeting. “Our results showed that the Decipher Prostate test was highly accurate in predicting aggressive prostate cancer in both groups. These findings confirm that use of the genomic test in African American men could potentially enable better treatment decisions and outcomes, helping to reduce outcome disparities for this population.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?